Prevention and treatment of cytomegalovirus infection in organ transplant recipients

Transplant Infectious Disease

Volumn 1, Issue 3, 1999, Pages 187-203

  Kusne, S ^a,b   Shapiro, R ^a   Fung, J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b University of Pittsburgh Medical Center ^*  (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Organ transplantation; Preemptive therapy; Prophylaxis; Resistance to antivirals

Indexed keywords

ANTIVIRUS AGENT;

CYTOMEGALIC INCLUSION BODY DISEASE; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; REVIEW; VIROLOGY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION IMMUNOLOGY;

EID: 0033188384     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.1999.010307.x     Document Type: Review

References (120)

1. ARNOLD JC, PORTMANN BC, OG'RADY JG, NAOUMOV NV, ALEXANDER GJM, WILLIAMS R. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992: 16: 285-292.
2. KENDALL TJ, et al. Cytomegalovirus and other herpesviruses: do they have a role in the development of accelerated coronary arterial disease in human heart allografts? J Heart Lung Transplant 1992: 2: S14-S20.
3. GRATTAN MT, MORENO-CABRAL CE, STARNES VA, OYER PE, STINSON EB, SHUMWAY NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc 1989: 261: 3561-3566.
4. DUNCAN SR, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992: 146: 1419-1425.
5. RAND KH, POLLARD RB, MERIGAN TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 1978: 298: 951-953.
6. VAN DEN BERG AP, et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant 1966: 10: 224-231.
7. GEORGE MJ, SNYDMAN DR, WERNER BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997: 103: 106-113.
8. FALAGAS ME, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997: 63: 1595-1601.
9. MANEZ R, et al. Post-transplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997: 176: 1462-1467.
10. HIBBERD PL, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial. Ann Intern Med 1995: 123: 18-26.
11. FIETZE E, et al. Cytomegalovirus infection in transplant recipients, the role of tumor necrosis factor. Transplantation 1994: 58: 675-680.
12. LJUNGMAN P, PLOTKIN SA. Workshop on CMV disease; definitions, clinical severity scores, and new syndromes. Scand J Infect Dis Suppl 1995: 99: 87-89.
13. LJUNGMAN P, GRIFFITHS P. Definitions of cytomegalovirus infection and disease. In: MICHELSON S, PLOTKIN AS, eds. Multidisciplinary approach to understanding cytomegalovirus desease. New York: Elsevier Science Publishers, 1993: 233-237.
14. RUBIN RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991: 324: 1057-1059.
15. MEYERS JD, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J M 1988: 318: 70-75.
16. GOODRICH JM, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991: 325: 1601-1607.
17. SCHMIDT GM, HORAK DA, NILAND JC, DUNCAN SR, FORMAN SJ, ZAIA JA and the City of Hope-Stanford-Synthex CMV Study Group. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991: 324: 1005-1011.
18. BALFOUR HH, CHACE BA, STAPLETON JT, SIMMONS RL, FRYD DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989: 320: 1381-1387.
19. DUNN DL, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994: 57: 876-884.
20. KLETZMAYR J, KOTZMANN H, KOVARIK J, KLAUSER R. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996: 7: 325-330.
21. RONDEAU E, et al. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993: 8: 858-862.
22. BRENNAN DC, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997: 12: 1843-1846.
23. AHSAN N, HOLMAN MJ, JANG HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transplant 1997: 11: 633-639.
24. BOWDEN RA, SAYERS M, FLOURNOY N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986: 314: 1006-1010.
25. RUUTU T, et al. No prevention of cytomegalovirus infection by anticytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transplant 1997: 19: 233-236.
26. SNYDMAN DR, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987: 317: 1049-1054.
27. CONTI DJ, FREED BM, GRUBER SA, LEMPERT N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients: A trial of ganciclovir vs. immunoglobulin. Arch Surg 1994: 129: 443-447.
28. MARTIN M, et al. A prospective randomized trial comparing sequential ganciclovir - high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994: 58: 779-785.
29. GREEN M, KAUFMANN M, WILSON J, REYES J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997: 25: 1344-1349.
30. SALIBA F, et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 1993: 25: 1444-1445.
31. GAVALDA J, et al. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transplant Int 1997: 10: 462-465.
32. WINSTON DJ, WIRIN D, SHAKED A, BUSUTTIL RW. Randomized comparison of ganciclovir and high dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995: 346: 69-47.
33. COHEN AT, O'GRADY JG, SUTHERLAND S, SALLIE R, TAN KC, WILLIAMS R. Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults. J Med Virol 1993: 40: 5-9.
34. SEU P, WLNSTON DJ, HOLT CD, KALDAS F, BUSUTTIL RW. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 1997: 64: 1614-1617.
35. GANE E, SALIBA F, VALDECASAS GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997: 350: 1729-1733.
36. SNYDMAN DR, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993: 119: 984-991.
37. KING SM, et al. Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin Infect Dis 1997: 25: 1173-9.
38. COFER JB, MORRIS CA, SUTKER WL, et al. A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Transplant Proc 1991: 23: 1525-1527.
39. MERIGAN TC, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992: 326: 1182-1186.
40. DUNCAN SR, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994: 150: 146-152.
41. KELLY JL, ALBERT RK, WOOD DE, RAGHU G. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995: 59: 1144-1147.
42. BAILEY TC, TRULOCK EP, ETTINGER NA, STORCH GA, COOPER JD, POWDERLY WG. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992: 165: 548-552.
43. CONTI DJ, FREED BM, SINGH TP, GALLICHIO M, GRUBER SA, LEMPERT N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg 1995: 130: 1217-1222.
44. TURGEON N, FISHMAN JA, BASGOZ N, et al. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 1998: 66: 1780-1786.
45. METSELAAR HJ, ROTHBARTH PH, BROUWER RML, et al. Prevention of cytomegalovirus-related death by passive immunization. Transplantation 1989: 48: 264-266.
46. STEINMULLER DR, NOVICK AC, STREEM SB, GRANETO D, SWIFT C. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation 1990: 49: 68-70.
47. GOTTI E, SUTER F, BARUZZO S, PERANI V, MOIOLI F, REMUZZI G. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin Transplant 1996: 10: 550-555.
48. SINGH N, YU VL, MIELES L, WAGENER MM, MINER RC, GAYOWSKI T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: a randomized trial. Ann Intern Med 1994: 120: 375-381.
49. GROSSI P, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996: 61: 1659-1660.
50. KUSNE S, GROSSI P, IRISH W, et al. CMV PP65 antigenemia monitoring as a guide for preemptive therapy: a cost-effective strategy for prevention of CMV disease in adult liver transplant recipients. Transplantation 1999: in press.
51. AGUADO JM, et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-CMV immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995: 39: 1643-1645.
52. IBERER F, et al. Definitions of cytomegalovirus disease after transplantation: Antigenemia as a marker for antiviral therapy. Transpl Int 1996: 9: 236-242.
53. EGAN JJ, et al. Preemptive treatment for the prevention of cytomegalovirus disease. Transplantation 1998: 65: 747-752.
54. PILLAY D, ALI AA, LIU SF, KOPS E, SWENY P, GRIFFITHS PD. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation 1993: 56: 103-108.
55. BAILEY TC, et al. Quantitative analysis of cytomegalovirus viremia in lung transplant recipients. J Infect Dis 1995: 171: 1006-1010.
56. FALAGAS ME, SNYDMAN DR, RUTHAZER R, WERNER BG, GRIFFITH J and the Boston Center for Liver Transplantation CMVIG Study Group. Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients. Clin Infect Dis 1997: 24: 824-829.
57. TANABE K. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 1997: 64: 1721-1725.
58. ERICE A, et al. Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes. J Clin Microbiol 1992: 30: 2822-2825.
59. REVELLO MG, PERCIVALLE E, MATTEO AD, MORINI F, GERNA G. Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients. J Gen Virol 1992: 73: 437-442.
60. THE TH, VAN DEN BERG AP, VAN SON WJ, et al. Monitoring for cytomegalovirus after organ transplantation: a clinical perspective. Transplant Proc 1993: 25: 5-9.
61. NIUBO J, et al. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis 1996: 24: 19-24.
62. VAN DEN BERG AP, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991: 164: 265-270.
63. THE TH, VAN DER PLOEG M, VAN DEN BERG AP, VLIEGER AM, VAN DER GIESSEN M, VAN SON WJ. Direct detection of cytomegalovirus in peripheral blood leukocytes - a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992: 543: 193-198.
64. GAETA A, NAZZARI C, ANGELETTI S, LAZZARINI M, MAZZEI E, MANCINI C. Monitoring for cytomegalovirus infection in organ transplant recipients: Analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes. J Med Virol 1997: 53: 189-195.
65. MURRAY BM, AMSTERDAM D, GRAY V, MYERS J, GERBASI J, VENUTO R. Monitoring and diagnosis of cytomegalovirus infection in renal transplantation. J Am Soc Nephrol 1997: 8: 1448-1457.
66. LO CY, et al. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Clin Transplant 1997: 11: 286-293.
67. KOSKINEN PK, NIEMINEN MS, MATTILA SP, HAYRY PJ, LAUTENSCHLAGER IT. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 1993: 55: 547-551.
68. EGAN JJ, et al. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1995: 50: 9-13.
69. VAN DEN BERG AP, et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation: A report of 130 consecutive patients. Transplantation 1989: 48: 991-995.
70. VAN DER BIJ W, TORENSMA R, VAN SON WJ, ANEMA J, SCHIRM J, TEGZESS AM, THE TH. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988: 25: 179-188.
71. GERNA G, REVELLO MG, PERCIVALLE E, MORINI F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992: 30: 1232-1237.
72. SEROPIAN S, FERGUSON D, SALLOUM E, COOPER D, LANDRY ML. Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant. Bone Marrow Transplant 1998: 22: 507-509.
73. GIUSEPPE G, et al. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 1991: 164: 488-498.
74. WOLFF C, et al. Significance of human cytomegalovirus DNA detection in immunocompromised heart transplant. Transplantation 1996: 61: 750-757.
75. BITSCH A, et al. The long persistence of CMV DNA in the blood of renal transplant patients after recovery from CMV infection. Transplantation 1993: 56: 108-113.
76. DELGADO R, et al. Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients. J Clin Microbiol 1992: 30: 1876-1878.
77. GROSSI P, MINOLI L, PERCIVALLE E, IRISH W, VIGANO M, GERNA G. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 1995: 59: 847-851.
78. STRATTA RJ, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989: 124: 1443-1450.
79. SAWYER MD, MAYORAL JL, GILLINGHAM KJ, KRAMER MA, DUNN DL. Treatment of recurrent cytomegalovirus disease in patients receiving solid organt transplants. Arch Surg 1993: 128: 165-170.
80. MANEZ R, BREINIG MK, KUSNE S, et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. Transplantation 1995: 59: 1220-1223.
81. RASMUSSEN L, MATKIN C, SPAETE R, PACHL C, MERIGAN TC. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 1991: 164: 835-842.
82. LUTZ E, WARD KN, GRAY JJ. Maturation of antibody avidity after primary human cytomegalovirus infection is delayed in immunosuppressed solid organ transplant patients. J Med Virol 1994: 44: 317-322.
83. VAN DEN BERG AP, et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation 1993: 55: 847-851.
84. BOIVIN G, ERICE A, CRANE DD, DUNN DL, BALFOUR JR HH. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993: 168: 332-335.
85. VAN DEN BURG AP, et al. Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes. J Infect Dis 1992: 166: 1228-35.
86. DROBYSKI WR, KNOX KK, CARRIGAN DR, ASH RC. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation 1991: 52: 155-157.
87. ROSEN HR, BENNER KG, FLORA KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997: 63: 476-478.
88. ALAIN S, HONDERLICK P, GRENET D, et al. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 1997: 63: 1533-1536.
89. BALDANTI F, SIMONCINI L, SARASINI A, et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 1998: 66: 324-329.
90. DREW WL, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991: 163: 716-719.
91. ERICE A, CHOU S, BIRON KK, STANAT SC, BALFOUR HH, JORDAN MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989: 320: 289-293.
92. BOIVIN G, ERICE A, CRANE DD, DUNN DL, BALFOUR HH Jr. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993: 168: 332-335.
93. LITTLER E, STUART AD, CHEE MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992: 358: 160-164.
94. DREW WL. Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance. J Aquir Immune Defic Syndr 1991: 4: S42-S46.
95. CHOU S, GUENTZEL S, MICHELS KR, MINER RC, DREW WL. Frequency of UL97 Phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995: 172: 239-242.
96. CHOU S, et al. Analysis of the UL97 Phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995: 171: 576-583.
97. SULLIVAN V, BIRON KK, TALARICO C, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993: 37: 19-25.
98. BALFOUR HH. Management of cytomegalovirus disease with antiviral drugs. Rev Infect Dis 1990: 12: S849-S860.
99. BUHLES WC, MASTRE BJ, TINKER AJ, STRAND V, KORETZ SH and the Syntex Collaborative Ganciclovir Treatment Study Group. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocomprised patients. Rev Infect Dis 1988: 10: S495-S506.
100. DUNN DL, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991: 51: 98-106.
101. STRATTA R, et al. Ganciclovir therapy for viral disease in liver transplant recipients. Transplant Proc 1991: 23: 1968.
102. KAPLAN CS, et al. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients. Arch Intern Med 1989: 149: 2095-2100.
103. MAYORAL JL, et al. Diagnosis and treatment of cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations. Arch Surg 1991: 126: 202-205.
104. PAYA CV, et al. Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection. Transplantation 1988: 46: 229-234.
105. ERICE A, JORDAN MC, CHACE BA, FLETCHER C, CHINNOCK BJ, BALFOUR HH. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. J Am Med Assoc 1987: 257: 3082-3087.
106. SMYTH RL, et al. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J Infect Dis 1991: 164: 1045-1050.
107. REED EC, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. Ann Intern Med 1990: 112: 505-510.
108. CHRISP P, CLISSOLD SP. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991: 41: 104-129.
109. IPPOLITI C, et al. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 1997: 20: 491-495.
110. LALEZARI JP, et al. (S)-1-[3-hydoxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995: 171: 788-796.
111. SNYDMAN DR. Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990: 12: S839-S848.
112. GLOWACKI LS, SMAILL FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - A meta-analysis. Clin Transplant 994: 8: 10-18.
113. RUBIN RH, LYNCH P, PASTERNACK MS, SCHOENFELD D, MEDEARIS DN. Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice. Antimicrob Agents Chemother 1989: 33: 1975-1979.
114. REED EC, BOWDEN RA, DANDLIKER PS, LILLEBY KE, MEYERS JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988: Nov 15: 783-788.
115. LJUNGMAN P, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992: 14: 83-835.
116. MEGISON SM, ANDREWS WS. Combination therapy with ganciclovir and intravenous IgG for cytomegalovirus infections in pediatric liver transplant recipients. Transplantation 1991: 52: 151-154.
117. D'ALESSANDRO AM, PIRSCH JD, STRATTA RJ, SOLLINGER HW, KALAYOGLU M, BELZER FO. Successful treatment of severe cytomegalovirus infections with ganciclovir and CMV hyperimmune globulin in liver transplant recipients. Transplant Proc 1989: 21: 3560-3561.
118. THE STUDIES OF OCULAR COMPLICATIONS OF AIDS RESEARCH GROUP IN COLLABORATION WITH THE AIDS CLINICAL TRIALS GROUP. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996: 114: 23-33.
119. MANISCHEWITZ JF, QUINNAN GV, LANE HC, WITTEK AE. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990: 34: 373-375.
120. BACIGALUPO A, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hematopoietic stem cell transplantation. Transplantation 1996: 62: 376-380.